{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:01:52Z","timestamp":1788321712685,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Minimizing hazardous drug (HD) contamination is critical for protecting the health of healthcare workers (HCWs) and patients. Alarmingly, widespread HD contamination has been documented across a variety of clinical settings. Quantitative wipe sampling presents significant time and cost barriers, resulting in routine monitoring adherence rates around 25%. Closed-system drug transfer devices (CSTDs) and qualitative point-of-care tests can be implemented to overcome these barriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we tested the effects of the BD PhaSeal Optima (Becton, Dickinson and Company), a recently introduced CSTD, on HD contamination at 2 chemotherapy infusion centers. Wipe samples were taken at 29 workstations at each location prior to and a year following CSTD implementation. Additionally, traditional liquid chromatography with mass spectrometry (LCMS\/MS) analyses were compared against a novel lateral flow immunoassay HD testing device (BD HD Check; Becton, Dickinson and Company) to determine the validity of the qualitative assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found a 46% reduction in HD contamination after incorporating the CSTD into clinical workflows. Across time points and sites, HD contamination reported by the BD HD Check device was 91% accurate against LCMS\/MS and 98% accurate within its limits of detection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Collectively, the evaluated CSTD and lateral flow immunoassay device may help to reduce HD contamination and provide real-time measures of contamination, respectively. As part of a multifaceted approach, these devices may help minimize barriers to routine monitoring, ultimately improving the safety of HCWs and patients.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxac336","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T17:19:01Z","timestamp":1668273541000},"page":"435-444","source":"Crossref","is-referenced-by-count":5,"title":["Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system"],"prefix":"10.1093","volume":"80","author":[{"given":"Erich","family":"Brechtelsbauer","sequence":"first","affiliation":[{"name":"Emory Healthcare and Winship Cancer Institute , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"2023032109035357300_","author":"National Institute for Occupational Safety and Health."},{"issue":"1-2","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mrgentox.2005.07.008","article-title":"Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees","volume":"587","author":"Cavallo","year":"2005","journal-title":"Mutat Res"},{"issue":"12","key":"2023032109035357300_","first-page":"855","article-title":"Leukaemia and reproductive outcome among nurses handling antineoplastic drugs","volume":"49","author":"Skov","year":"1992","journal-title":"Br J Ind Med"},{"issue":"3","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.0954-6820.1983.tb08593.x","article-title":"Liver damage in nurses handling cytostatic agents","volume":"214","author":"Sotaniemi","year":"1983","journal-title":"Acta Med Scand"},{"issue":"4","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"327.e1","DOI":"10.1016\/j.ajog.2011.12.030","article-title":"Occupational exposures among nurses and risk of spontaneous abortion","volume":"206","author":"Lawson","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/JOM.0b013e3181f73ae6","article-title":"Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs","volume":"52","author":"McDiarmid","year":"2010","journal-title":"J Occup Environ Med"},{"issue":"9","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/15459624.2016.1165912","article-title":"Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: methodology and recommendations","volume":"13","author":"Connor","year":"2016","journal-title":"J Occup Environ Hyg"},{"issue":"8","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/15459624.2017.1316389","article-title":"Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 Canadian hospitals: a 2016 follow-up study","volume":"14","author":"Roland","year":"2017","journal-title":"J Occup Environ Hyg"},{"issue":"3","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1188\/20.ONF.263-272","article-title":"Surface contamination with antineoplastic drugs on two inpatient oncology units","volume":"47","author":"Walton","year":"2020","journal-title":"Oncol Nurs Forum"},{"issue":"9","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/ajhp\/zxz033","article-title":"Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies","volume":"76","author":"Salch","year":"2019","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2146\/ajhp160948","article-title":"Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs","volume":"75","author":"Bartel","year":"2018","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/2193-1801-2-273","article-title":"Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital","volume":"2","author":"Miyake","year":"2013","journal-title":"Springerplus"},{"issue":"1","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1078155209352543","article-title":"Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device","volume":"16","author":"Siderov","year":"2010","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1310\/hpj4803-204","article-title":"Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device","volume":"48","author":"Sessink","year":"2013","journal-title":"Hosp Pharm"},{"issue":"17","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/ajhp\/zxab134","article-title":"Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination","volume":"78","author":"Gabay","year":"2021","journal-title":"Am J Health-Syst Pharm"},{"issue":"2","key":"2023032109035357300_","first-page":"96","article-title":"Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH)","volume":"45","author":"Valero-Garc\u00eda","year":"2021","journal-title":"Farm Hosp"},{"key":"2023032109035357300_","author":"US Pharmacopeial Convention."},{"key":"2023032109035357300_","first-page":"3","article-title":"Environmental contamination with cytostatic drugs: past, present, and future.","volume-title":"Safety Considerations in Oncology Pharmacy","author":"Sessink","year":"2011"},{"key":"2023032109035357300_","author":"Wipe analysis."},{"key":"2023032109035357300_","author":"Becton Dickinson and Company."},{"issue":"3","key":"2023032109035357300_","first-page":"107","article-title":"New approaches to wipe sampling methods for antineoplastic and other hazardous drugs in healthcare settings","volume":"1","author":"Connor","year":"2016","journal-title":"Pharm Technol Hosp Pharm"},{"key":"2023032109035357300_","author":"National Institute for Occupational Safety and Health."},{"issue":"suppl 1","key":"2023032109035357300_","first-page":"1","article-title":"ISOPP standards of practice. Safe handling of cytotoxics","volume":"13","author":"International Society of Oncology Pharmacy Practitioners Standards Committee.","year":"2007","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1177\/1078155218787256","article-title":"Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs","volume":"25","author":"Forshay","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1078155212468367","article-title":"Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents","volume":"19","author":"Clark","year":"2013","journal-title":"J Oncol Pharm Pract"},{"key":"2023032109035357300_","article-title":"Closed-system drug transfer devices: comparative study of different models.","author":"Masson","year":"2018"},{"issue":"10","key":"2023032109035357300_","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.12968\/bjon.2020.29.10.S15","article-title":"Use of a closed-system drug transfer device reduces contamination with doxorubicin during bolus injection","volume":"29","author":"Marler-Hausen","year":"2020","journal-title":"Br J Nurs"},{"key":"2023032109035357300_","author":"Becton, Dickinson and Company."},{"key":"2023032109035357300_","first-page":"1","author":"Becton, Dickinson and Company.","year":"2019"},{"key":"2023032109035357300_","first-page":"1","author":"Becton, Dickinson and Company.","year":"2019"},{"key":"2023032109035357300_","author":"Becton Dickinson and Company."},{"key":"2023032109035357300_","author":"Elcam Medical."},{"issue":"4","key":"2023032109035357300_","first-page":"444","article-title":"Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies \u2013 the MEWIP project","volume":"57","author":"Kiffmeyer","year":"2013","journal-title":"Ann Occup Hyg"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac336\/47887547\/zxac336.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/7\/435\/49561734\/zxac336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/7\/435\/49561734\/zxac336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T18:41:40Z","timestamp":1701369700000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/7\/435\/6825401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,11,12]]},"published-print":{"date-parts":[[2023,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac336","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,11,12]]}}}